The Russian Direct Investment Fund (RDIF) approved a single-dose version of the Sputnik V coronavirus vaccine. Announcing this, RDIF also said that Sputnik Light “demonstrated 79.4 percent efficacy” compared to 91.6 percent for the two-shot Sputnik V.
The results, it said, were drawn from “data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021”.
“Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center, during laboratory tests,” the statement added.
The efficacy rate was calculated based on data obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination programme between December 5 and April 15.
“The Sputnik Light vaccine significantly reduces the possibility of severe cases leading to hospitalization, with only one injection needed. The single dose regimen solves the challenge of immunizing large groups in a shorter time, which is especially important during the acute phase of the spread of coronavirus, achieving herd immunity faster,” said Kirill Dmitriev, CEO of RDIF.
Dmitriev said that the Sputnik Light vaccine will be exported to the international partners “to help increase the rate of vaccinations in a number of countries in the face of the ongoing fight with the pandemic and new strains of coronavirus”.
The Sputnik Light vaccine has received authorization for use in Russia, according to the Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the RDIF.
The Russian vaccine has been approved for use in over 60 countries.
But it has not yet been approved by the European Medicines Agency (EMA) or the United States’ Food and Drug Administration (FDA).